Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.66 USD | +2.01% | +0.94% | -31.92% |
Financials (USD)
Sales 2024 * | 510M | Sales 2025 * | 643M | Capitalization | 2.86B |
---|---|---|---|---|---|
Net income 2024 * | -64M | Net income 2025 * | 68M | EV / Sales 2024 * | 5.96 x |
Net Debt 2024 * | 182M | Net Debt 2025 * | 84.17M | EV / Sales 2025 * | 4.58 x |
P/E ratio 2024 * |
-45.8
x | P/E ratio 2025 * |
43.9
x | Employees | 517 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.81% |
Latest transcript on Amicus Therapeutics, Inc.
1 day | +2.01% | ||
1 week | +0.94% | ||
Current month | -3.30% | ||
1 month | -8.35% | ||
3 months | -28.60% | ||
6 months | -8.78% | ||
Current year | -31.92% |
Managers | Title | Age | Since |
---|---|---|---|
Bradley Campbell
CEO | Chief Executive Officer | 48 | 06-03-31 |
Simon Harford
DFI | Director of Finance/CFO | 64 | 23-08-20 |
Pat O’Sullivan
COO | Chief Operating Officer | - | 22-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bradley Campbell
CEO | Chief Executive Officer | 48 | 06-03-31 |
Lynn Bleil
BRD | Director/Board Member | 60 | 18-09-10 |
Burke Whitman
BRD | Director/Board Member | 68 | 19-06-26 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.91% | 14 M€ | -5.30% | ||
0.32% | 0 M€ | 0.00% | - | |
0.29% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 9.66 | +2.01% | 3,165,807 |
24-05-23 | 9.47 | -2.57% | 2,784,813 |
24-05-22 | 9.72 | -1.92% | 2,160,926 |
24-05-21 | 9.91 | +1.64% | 2,203,687 |
24-05-20 | 9.75 | +1.88% | 1,984,894 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.92% | 2.86B | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- FOLD Stock